92 212

Cited 3 times in

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

Authors
 Hyeon Gyu Yi  ;  Jin Seok Kim  ;  Cheolwon Suh  ;  Won Seog Kim  ;  Jae-Yong Kwak  ;  Jong-Seok Lee  ;  Yang Soo Kim  ;  Young Don Joo  ;  Yoo Hong Min  ;  Hong Ghi Lee  ;  Sung-Soo Yoon  ;  Jong-Ho Won  ;  Seonyang Park  ;  Hugh Chul Kim  ;  Chul Soo Kim 
Citation
 BLOOD RESEARCH, Vol.48(2) : 115-120, 2013 
Journal Title
 BLOOD RESEARCH 
ISSN
 2287-979X 
Issue Date
2013
Keywords
CHOP regimen ; Diffuse large B-cell lymphoma ; Epidemiology ; Rituximab ; Survival
Abstract
BACKGROUND: This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. METHODS: In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990. RESULTS: Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration. CONCLUSION: The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.
Files in This Item:
T201305312.pdf Download
DOI
10.5045/br.2013.48.2.115
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88933
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse